Trial Profile
Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Fimepinostat (Primary)
- Indications B-cell lymphoma; CNS cancer; Diffuse intrinsic pontine glioma; Lymphoma; Neuroblastoma; Solid tumours
- Focus Adverse reactions
- 07 Mar 2024 Planned End Date changed from 1 Jan 2024 to 1 Jul 2024.
- 07 Mar 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jul 2024.
- 07 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.